QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.35 (-2.22%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.62 (-1.73%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.34%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)
QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.35 (-2.22%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.62 (-1.73%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.34%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)
QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.35 (-2.22%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.62 (-1.73%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.34%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)
QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.35 (-2.22%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.62 (-1.73%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.34%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)

Geron (GERN) Stock Price, News & Analysis

$1.93
-0.14 (-6.76%)
(As of 04:00 PM ET)
Compare
Today's Range
$1.88
$2.07
50-Day Range
$1.74
$2.09
52-Week Range
$1.68
$3.84
Volume
4.90 million shs
Average Volume
6.54 million shs
Market Capitalization
$1.05 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.75

Geron MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
146.1% Upside
$4.75 Price Target
Short Interest
Bearish
8.19% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-3.05
Upright™ Environmental Score
News Sentiment
0.72mentions of Geron in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.35) to ($0.31) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

485th out of 945 stocks

Pharmaceutical Preparations Industry

216th out of 436 stocks


GERN stock logo

About Geron Stock (NASDAQ:GERN)

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

GERN Stock Price History

GERN Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Geron Corporation Q3 Loss beats estimates
4GERN : Geron Earnings Preview
Techne (TECH) Q1 Earnings and Revenues Miss Estimates
Geron Corporation Stock: Another Buying Opportunity
Goldman Sachs Upgrades Geron (GERN)
See More Headlines
Receive GERN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Geron and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2023
Today
12/11/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/21/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:GERN
CUSIP
37416310
Employees
107
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.75
High Stock Price Target
$6.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+144.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-141,900,000.00
Net Margins
-55,138.49%
Pretax Margin
-55,138.49%

Debt

Sales & Book Value

Annual Sales
$600,000.00
Book Value
$0.20 per share

Miscellaneous

Free Float
526,229,000
Market Cap
$1.05 billion
Optionable
Optionable
Beta
0.79
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. John A. Scarlett M.D. (Age 72)
    Chairman of the Board, President & CEO
    Comp: $1.53M
  • Dr. Andrew J. Grethlein (Age 59)
    Executive VP & COO
    Comp: $847.2k
  • Ms. Michelle J. Robertson (Age 56)
    Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer
  • Ms. Aron Feingold
    Vice President of Investor Relations & Corporate Communications
  • Mr. Scott Samuels
    Executive VP, Chief Legal Officer & Corporate Secretary
  • Ms. Shannon Odam
    Vice President of Human Resources
  • Ms. Melissa A. Kelly Behrs (Age 59)
    Executive VP of Business Operations & Chief Alliance Officer
    Comp: $753.22k
  • Mr. Anil Kapur (Age 53)
    Executive VP of Corporate Strategy & Chief Commercial Officer
    Comp: $654.89k
  • Mr. Edward E. Koval (Age 61)
    Executive VP & Chief Business Officer
  • Dr. Faye Feller M.D. (Age 41)
    Executive VP & Chief Medical Officer














GERN Stock Analysis - Frequently Asked Questions

Should I buy or sell Geron stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GERN shares.
View GERN analyst ratings
or view top-rated stocks.

What is Geron's stock price target for 2024?

3 brokers have issued 12 month price objectives for Geron's shares. Their GERN share price targets range from $4.00 to $6.00. On average, they anticipate the company's share price to reach $4.75 in the next twelve months. This suggests a possible upside of 146.1% from the stock's current price.
View analysts price targets for GERN
or view top-rated stocks among Wall Street analysts.

How have GERN shares performed in 2023?

Geron's stock was trading at $2.42 at the beginning of 2023. Since then, GERN shares have decreased by 20.2% and is now trading at $1.93.
View the best growth stocks for 2023 here
.

When is Geron's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our GERN earnings forecast
.

How were Geron's earnings last quarter?

Geron Co. (NASDAQ:GERN) released its quarterly earnings results on Thursday, November, 2nd. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.10) by $0.02. The biopharmaceutical company had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.14 million. Geron had a negative net margin of 55,138.49% and a negative trailing twelve-month return on equity of 70.26%.

What ETFs hold Geron's stock?
What is John A. Scarlett's approval rating as Geron's CEO?

5 employees have rated Geron Chief Executive Officer John A. Scarlett on Glassdoor.com. John A. Scarlett has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Geron own?
Who are Geron's major shareholders?

Geron's stock is owned by a number of institutional and retail investors. Top institutional investors include RA Capital Management L.P. (8.51%), MPM Bioimpact LLC (1.97%), Wellington Management Group LLP (1.92%), FMR LLC (1.39%), Northern Trust Corp (0.99%) and Invesco Ltd. (0.84%). Insiders that own company stock include Andrew J Grethlein, Elizabeth G O'farrell, John A Scarlett, Olivia Kyusuk Bloom, Susan Molineaux and V Bryan Lawlis.
View institutional ownership trends
.

How do I buy shares of Geron?

Shares of GERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:GERN) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -